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Abstract: Following guideline recommendations to promote tobacco prevention in adolescent
primary care, we developed a patient-facing clinical support tool. The electronic tool screens
patients for use and susceptibility to conventional and alternative tobacco products, and promotes
patient–provider communication. The purpose of this paper is to describe the iterative stakeholder
engagement process used in the development of the tool. During the pre-testing phase, we consulted
with scientists, methodologists, clinicians, and Citizen Scientists. Throughout the development
phase, we engaged providers from three clinics in focus groups. Usability testing was conducted via
in-depth, cognitive interviewing of adolescent patients. Citizen Scientists (n = 7) played a critical role
in the final selection of educational content and interviewer training by participating in mock-up
patient interviews. Cognitive interviews with patients (n = 16) ensured that systems were in place
for the feasibility trial and assessed ease of navigation. Focus group participants (n = 24) offered
recommendations for integrating the tool into clinical workflow and input on acceptability and
appropriateness, and anticipated barriers and facilitators for adoption and feasibility. Engaging
key stakeholders to discuss implementation outcomes throughout the implementation process can
improve the quality, applicability, and relevance of the research, and enhance implementation success.
Keywords: tobacco; smoking; e-cigarettes; vaping; electronic health record; patient portal
1. Introduction
The US Preventive Services Task Force and the American Academy of Pediatrics (AAP)
recommend that primary care providers (PCP) use interventions such as patient education or brief
counseling to prevent tobacco use in adolescents [1,2]. Adolescents identify healthcare providers as
their preferred information source regarding smoking [3,4], and parents are supportive of provider
screening and counseling for tobacco use [5,6]. PCPs have unique opportunities to prevent tobacco use
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initiation and nicotine addiction in their patients, identify current tobacco use in both adolescents and
parents, and initiate or refer for treatment [7].
Despite consensus regarding tobacco prevention recommendations, many PCPs do not routinely
assess and counsel adolescents about tobacco use [8]. Reasons cited for this practice gap include lack
of clear clinical practice guidelines, lack of training, and perception of low self-efficacy in delivering
effective interventions [9]. Although the prevalence of cigarette smoking among adolescents has
declined [10], the use of noncigarette tobacco and nicotine products is rising steeply [7], reflecting the
increasing heterogeneity of tobacco product use among adolescents [11]. The probability of developing
nicotine dependence and tobacco-related diseases increases with younger initiation and longer use [2].
Further, present-day adolescents who use tobacco are more likely to be from socially disadvantaged
groups than in previous decades [12]. Consequently, traditional approaches to prevention may have
limited fit and reach for current adolescents, given their nontraditional tobacco use patterns as well as
the changing demographics of users.
Clinically efficient strategies can support providers in meeting tobacco control recommendations,
but have been insufficiently implemented in adolescent primary care. Given the evolving tobacco
product landscape, research needs to expand traditional strategies to address the array of tobacco
products now available to adolescents. Additionally, due to the time constraints on clinical encounters,
proposed interventions must achieve appropriate fit within existing clinical workflows [1,13,14].
Addressing these knowledge gaps can expand the reach of effective interventions, and improve
intervention delivery, implementation, and sustainability. In response to these challenges, our team
proposed developing an electronic clinical support tool to screen adolescent patients for use of or
susceptibility to any tobacco product, and to promote provider-based tobacco counseling along with
the delivery of brief media messages from the Food and Drug Administration (FDA)’s youth tobacco
prevention campaign [15].
Interventions to improve the translation of evidence-based recommendations may substantially
lower tobacco initiation and use rates. In recognition of the degree to which the engagement of multiple
stakeholders prior to and during the implementation process can promote its success [16], our team
engaged relevant stakeholders early in the intervention development phase. Accordingly, the purpose
of this report is to describe the stakeholder engagement process used in intervention development.
2. Methods
2.1. Research Setting
The formative research described herein was approved by the University of Florida (UF)
Institutional Review Board and conducted in collaboration with primary care clinics from the UF
Health System, with representation from both pediatrics and family medicine. The clinics serve urban
and rural communities in North Florida with large variations across clinics by income, education, and
racial/ethnic minority status [17]. Additionally, UF Health is a member of the OneFlorida Clinical
Research Consortium [18] and future phases of this project will involve scaling up the intervention to
other health systems in the consortium. OneFlorida is a research collaborative comprising 22 hospitals,
1240 medical practices, 4000+ physician providers, and 11 million patients statewide [18]. The
consortium provides a substantial research foundation with a centralized Institutional Review Board,
shared governance, and implementation support from a network of practice facilitators and providers.
2.2. Stakeholders
We purposefully engaged various and diverse stakeholders, including scientists, clinicians,
patients, and Citizen Scientists—a group of community members who fulfill the critical role of
providing the patient and family perspective on clinical and translational research. Our team also
collaborated with the health system clinics and information technology group. The following sections
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describe the Citizen Scientist program outlining the various steps in the stakeholder engagement
process (Figure 1).
Children 2018, 5, 170  3  of  10 
 
 
Figure 1. Stakeholder engagement timeline. 
2.3. The Citizen Scientist Program 
The Citizen Scientist Program is a resource of the UF Clinical and Translational Science Institute 
(CTSI)  and  OneFlorida  that  bridges  the  gap  between  researchers  and  community  members.  It 
engages patients,  caregivers and other  community members, who may or may not have  specific 
health conditions, as meaningful collaborators throughout the research process. Citizen Scientists are 
CTSI employees who offer a lay perspective in proposal review, patient recruitment strategies, and 
other  areas where  stakeholder  engagement  is needed. The program  includes  a diverse  group  of 
participants who vary by gender, age (as young as 15), race, ethnicity, and cultural background. 
2.4. Step 1: Implementation Science Studio 
The  proposed  intervention  was  initially  presented  at  an  Implementation  Science  Studio 
organized  by  the  UF  CTSI.  These  studios  are  multidisciplinary  roundtable  discussions  of 
implementation research proposals, attended by several scientists, clinicians, research coordinators, 
and Citizen Scientists. Participants provide concrete and actionable advice on research proposals. 
Although the studios support projects at any stage, they are particularly appropriate for the formative 
stage of development. The studio allowed us to propose our idea to a group of fellow researchers, 
including  methodologists  and  clinician  scientists,  in  addition  to  representatives  of  the  Citizen 
Scientist Program. 
2.5. Step 2: Consultations with Citizen Scientists 
With  studio  discussion  feedback,  our  research  team  developed  the  first  prototype  of  the 
electronic  tool and sought  input on  initial content of  the  tool  through several  follow‐up meetings 
specifically with five young Citizen Scientists (3 females and 2 males, age range 15–20), who more 
closely resembled the target patient audience for the intervention. The Citizen Scientists were asked 
to  critique  and validate  the  screening questions  and  rank order various  image‐  and video‐based 
health messages from the FDA’s tobacco prevention campaign [15]. Following Proctor’s Framework 
for  Implementation  Outcomes,  [19]  the  Citizen  Scientists  also  provided  feedback  on  the  tool’s 
acceptability  (degree  to  which  the  intervention  is  “agreeable,  palatable,  or  satisfactory”  to 
stakeholders) and appropriateness (perceived “fit, relevance, or compatibility” for the clinical setting 
and problem). 
2.6. Step 3: Provider Focus Group Discussions 
We  conducted  provider  focus  groups  in  three  pediatric  clinics  with  24  total  participants 
(physicians, nurses, nurse practitioners, and office staff) to identify relevant barriers and facilitators 
to  implementation. Guided by Proctor’s Framework  for  Implementation Outcomes  [19],  the  focus 
groups addressed four relevant outcomes: acceptability, adoption, appropriateness, and feasibility of 
the intervention within the context of clinical workflow. They were conducted by trained moderators 
at three stages of the intervention development, whereby participants in the initial focus group were 
Figure 1. Stakeholder engagement timeline.
2.3. The Citizen Scientist Program
The Citizen Scientist Program is a resource of the UF Clinical and Translational Science Institute
(CTSI) and OneFlorida that bridges the gap between researchers and community members. It engages
patients, caregivers and other community members, who may or may not have specific health
conditions, as meaningful collaborators throughout the research process. Citizen Scientists are CTSI
employees who offer a lay perspective in proposal review, patient recruitment strategies, and other
areas where stakeholder engagement is needed. The program includes a diverse group of participants
who vary by gender, age (as young as 15), race, ethnicity, and cultural background.
2.4. Step 1: Implementation Science Studio
The proposed intervention was initially presented at an Implementation Science Studio organized
by the UF CTSI. These studios are multidisciplinary roundtable discussions of implementation research
proposals, attended by several scientists, clinicians, research coordinators, and Citizen Scientists.
Participants provide concrete and actionable advice on research proposals. Although the studios
support projects at any stage, they are particularly appropriate for the formative stage of development.
The studio allowed us to propose our idea to a group of fellow researchers, including methodologists
and clinician scientists, in addition to representatives of the Citizen Scientist Program.
2.5. Step 2: Consultations with Citizen Scientists
With studio discussion feedback, our re earch team developed the first prototype of the electronic
tool and sought input on initial content of the tool through several follow-up meetings specifically with
five young Citizen Scientists (3 females and 2 males, age range 15–20), who more closely resembled
the target patient audience for the intervention. The Citizen Scientists were asked to critique and
validate the screening questions and rank order various image- and video-based health messages from
the FDA’s tobacco prevention campaign [15]. Following Proctor’s Framework for Implementation
Outcomes [19], the Citizen Scientists also provided feedback on the tool’s acceptability (degree to
which the intervention is “agreeable, palatable, or satisfactory” to stakeholders) and appropriateness
(perceived “fit, relevance, or compatibility” for the clinical setting and problem).
2.6. Step 3: Provider Focus Group Discussions
We conducted provider focus groups in three pediatric clinics with 24 total participants
(physicians, nurs s, nur e practitioners, and office staff) to identify relevant barriers and facilitators
to implementation. Guided by Proctor’s Framework for Implementation Outcomes [19], the focus
groups addressed four relevant outcomes: acceptability, adoption, appropriateness, and feasibility of
the intervention within the context of clinical workflow. They were conducted by trained moderators
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at three stages of the intervention development, whereby participants in the initial focus group were
presented with a prototype of the electronic tool (developed with feedback from the studio and further
refined following Citizen Scientist consultations), and the latter two focus groups tested iterations of
the tool that were informed by prior focus groups. Focus groups lasted 45 min on average, and were
audiorecorded for transcription and analysis.
2.7. Step 4: Patient Interviews
After mock-up interviews with Citizen Scientists, usability testing of the electronic tool was
conducted via in-depth, cognitive interviewing of 16 adolescent patients (9 females and 7 males, 7 were
12–14 years old and 9 were 15–17 years) recruited from the UF Adolescent Clinic. This clinic mostly
serves Medicaid recipients (80%) and is racially and ethnically diverse, with patients evenly divided
between African American and white adolescents and roughly 10% being Hispanic adolescents [17].
The interviewed patients included 3 non-Hispanic blacks, 4 Hispanics, 3 non-Hispanic whites, and
patients of mixed/other race(s). Participants were either tobacco users (n = 2) or determined to
be susceptible to tobacco use (i.e., lack of a firm commitment to avoid tobacco use; n = 14) [20,21].
The following three questions were used to determine susceptibility: (1) “If one of your friends
offered you a cigarette, e-cigarette, or another tobacco product, would you use it?” (2) “At any time
during the next 12 months, do you think you will use cigarettes, e-cigarettes, or another tobacco
product?” (3) “Do you think you will be using cigarettes, e-cigarettes, or another tobacco product
five years from now?” Response options were “definitely yes”, “probably yes”, “probably not”,
“definitely not”, and “don’t know”. Those who responded with “definitely not” to all three questions
were considered not susceptible to cigarette smoking, whereas all other participants were considered
susceptible. Adolescents were asked about their perceptions and attitudes concerning tobacco products,
their personal experiences with tobacco products, and their opinions of the prototype tool. The
interviews therefore ensured that all systems were in place for implementation, assessed ease of
navigation by adolescents, and provided important information needed to tailor the tool to local clinical
settings. Patient interviews allowed us to validate the intervention design and ensure acceptability
and appropriateness among the target audience. The interviews were moderated by two researchers
trained in qualitative methods, and were audio recorded for subsequent transcription and analysis.
2.8. Step 5: Citizen Scientist Debriefing
At the conclusion of the formative phase of the project, the investigators reconvened the Citizen
Scientists to demonstrate the final product and provide them with information on how their feedback
was incorporated into the study design.
2.9. Data Analysis
Analysis of focus group and interview transcripts was conducted concurrently with data collection
to ensure that emerging themes could inform refinements to both the support tool and to the moderator
guides. For both types of data, the analytic approach involved an initial phase of deductive coding
(using codes derived from the research questions) and a secondary phase of inductive coding
(generating new codes to assign to emerging themes) [22]. Separate codebooks for the provider
focus groups and adolescent interviews were developed iteratively, and transcripts were back-coded
with emerging themes identified during the inductive phase. To address inter-rater reliability, each
transcript was coded independently by two trained coders, and team meetings were held to discuss
and obtain consensus on coding discrepancies [23].
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3. Results
3.1. Intervention Characteristics
Our team developed the tool integrating into a health risk assessment process administered via
the patient portal and validated by stakeholder feedback throughout the intervention development
process (Figure 2). The decision to integrate tobacco screening into the health risk assessment in the
patient portal and the process of developing the tool resulted from key stakeholder recommendations.
The questionnaire (Supplementary File 1) appears in the patient’s portal inbox when scheduled for a
well-child visit, and can be completed prior to or upon arrival in the clinic. Patients who are unable to
enroll in the patient portal due to time constraints are offered the questionnaire via the electronic health
record (EHR) system in the examination room. The tool screens adolescents for tobacco use (including
cigarette smoking and use of non-cigarette tobacco products), parental tobacco use, and susceptibility
to using tobacco products [20,21]. In addition, the adolescent is shown a brief video from the FDA’s
campaign [15,24], for which acceptability has already been demonstrated among adolescents [15,24].
The specific video content that appears is based on patient responses about the tobacco product(s) they
use and their preferences regarding the tobacco-related health message topic they are most likely to
discuss with the provider. The provider views a synopsis of the questionnaire responses (including
video topic) in the EHR prior to counseling the patient.
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Figure 2. Electronic health record (EHR)-based screening clinic workflow.
3.2. Implementation Science Studio and Citizen Scientist Contributions
Feedback from the studio and Citizen Scientist consultations highlighted the importance of
screening for non-cigarette products, intervention with susceptible non-users, and completion time,
ensuring that the tool was streamlined to optimize its fit into clinical workflow. These consultations also
prepared the research team for our initial interactions with the end-users by raising critical preliminary
questions and potential barriers, such as patient confidentiality and health literacy, that were included
in the development of the focus group and interview guides with the end-users.
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3.3. Focus Group Findings
Integration of the tool into clinical workflow was the most common theme in focus groups.
Providers expressed concerns about “adding one more thing” to do in clinical encounters where time
is already limited, and discussed ways they could adapt clinical workflow or use existing resources to
accommodate the tool. As one provider noted:
“There could be potentially an office policy that says, ‘This patient is going to go into this room, fills
this out.’ And have them do a survey in that area as they are checking in. That could potentially work.
But, if we are doing it at the point where the nurses are already with everyone, there could be a pretty
big disruption in flow.”
In the first focus group, providers were presented a version of the tool that was intended for
completion on a tablet device in the waiting room (prior to the adolescent’s appointment). This format
raised questions about how the tool would be administered in a way that would ensure confidentiality,
as parents could easily see the screen and their child’s responses to the survey. The providers proposed
solutions that could address both workflow and confidentiality issues, such as integrating the tool
with intake forms already used in well-care visits, and allowing for a web-based option that could be
completed on the patients’ own devices or at home prior to their visit.
This feedback led to critical enhancements to the intervention, including its integration into
the patient portal platform and incorporating the AAP’s Bright Futures health risk assessment [25]
(previously in paper form) into the electronic questionnaire. Building the tool within the patient portal
furthered its integration with common clinic processes, streamlined patient accessibility, reduced
clinical burden, and addressed concerns about confidentiality. The idea of integrating the tool with
existing clinical processes, rather than trying to adapt workflow to accommodate the tool, resonated
with many providers. With these modifications, the tool would not only fulfill its own function to
support tobacco screening and counseling, but also introduce efficiencies to clinical workflow generally.
As one provider stated:
“I think that’s the wave of the future. Why are we filling out forms? They fill out the same thing
time and time again. A patient writes on the form, checks these things off, and then I take what they
wrote and I type it into the computer... I’m repeating unnecessary work. Wouldn’t it be more efficient
it they could type it in? It automatically goes to [the patient portal], automatically populates here
every time.”
Providers and clinic staff were also supportive of utilizing the patient portal because the health
system had opted to designate a version specifically for adolescents (ages 12–17 years) to maximize
confidentiality in compliance with state privacy laws [26]. This innovative adaptation ensured that
the implementation of meaningful use requirements aligned with the goals of adolescent health. One
participant remarked that this was especially important for younger adolescents whose parents are
often present during the clinical encounter:
“I truly see that as an advantage of your process . . . I think that adolescents are going to feel like their
privacy is better protected if they can [do it] on their iPhone, their iPad, or at home prior to the clinic
visit. Enter this data, but be reassured and know that it’s going to be protected and kept away from
their parent.”
Furthermore, these enhancements are expected to increase acceptability and sustainability, given
that increasing patient portal enrollment and implementing Bright FuturesTM are two initiatives with
strong organizational support at UF Health. Consistent with the Diffusion of Innovation Theory [27],
bundling the tool with an electronic version of Bright FuturesTM increases relative advantage to clinics.
3.4. Patient Interview Findings
Interviews with patients provided us with the opportunity to validate the intervention design and
ensure acceptability and appropriateness among the target audience. By completing the questionnaire
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during the interview, patients confirmed initial feasibility of the tool prior to implementation in the
clinic. This included an assessment of content (relevance and comprehension of the survey questions,
images, and videos) and function (ease of use and navigation). Interview participants considered the
intervention content to be relevant to teens their age, and favorably viewed the proposed method of
completing the tool using the patient portal.
Acceptability of the tool by adolescents was high; nearly all participants considered the tool
easy to use and expressed positive views about the tool. In particular, adolescents valued that the
tool focused on not only the health consequences of using tobacco products, but also the social
consequences that result from the effects of tobacco use on physical appearance and the cost of tobacco
products. Some adolescents viewed the screener favorably because it asked about smoking by family
members and friends. Two commented on questions from the susceptibility screener, stating they
liked how the tool asked whether they would use tobacco if one of their friends offered it to them—a
question that acknowledges social influence as an important element of susceptibility. However,
another adolescent reported having trouble grasping the third susceptibility question (using tobacco
“5 years from now”), remarking that it seemed “a little far off”. With regard to family, one 14-year-old
participant mentioned that her father and other family members smoked cigarettes, and that because
of this she had considered trying cigarettes herself. When asked what she liked about the screening
questions, she noted:
“The questions were about teens, which is okay. And then we were asked about the family on the
survey. I liked it because it shows how smoking could come from the family members around you.
You’re seeing it everywhere you go.”
Furthermore, the views of adolescent participants on confidentiality aligned largely with the
perspectives of providers. Most adolescents expressed a preference for completing the tool at home
(using the patient portal) rather than in the doctor’s office, both because the portal allows for more
privacy and because the home is a more comfortable setting. Although only two participants reported
having ever used tobacco, most adolescents recognized that their peers who did use tobacco would be
discouraged from responding to the screener honestly if measures were not taken to ensure privacy.
As one 16-year-old male participant noted:
“Some teenagers, they feel like they don’t want to write so honestly. It all depends on the teenager . . .
They’re not supposed to be doing stuff like that. They’re not supposed to be using tobacco or anything.
They’re probably afraid that the person they’re talking to would go tell their parents or something.”
Although findings from the adolescent interviews did not ultimately inform substantive changes
to the tool, as end-users their perspectives were critical for validating the design and usability of the
tool, as well as triangulating and adding context to the perspectives of providers.
3.5. Debrief Findings
The Citizen Scientists welcomed the update from the research team and were pleased their
contributions to science were valued. Closing the feedback loop with them was an integral component
of the stakeholder engagement process.
4. Discussion
We deliberately engaged multiple stakeholders in the development of a clinical support tool
using a combination of traditional methods (focus groups and interviews) and more novel resources
(Implementation Science Studio and Citizen Scientists). The innovative tool is comprehensive in
its content (e.g., screens for non-cigarette products, susceptibility, parental tobacco use, and other
risk factors), and delivers tobacco prevention video messages tailored to adolescents. Following the
iterative stakeholder engagement process, the tool evolved as a result of several adaptations to the
initial prototype. The resulting intervention is embedded into the health risk assessment process and
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integrated into the EHR system and patient portal, as well as clinical workflow. All of these features
are expected to increase the acceptability and sustainability of the tool in clinical practice.
Electronic health record systems offer easy-to-access regulatory-compliant methods to document
assessment and counseling provided during a medical encounter with adolescent patients. Further
EHR automation provides a sustainability advantage over prior interventions [28–30] that relied on
in-clinic and post-visit staff support. Whereas EHR-based tobacco control interventions have been
effective in adults [31–33], fewer efforts have been made to develop clinically efficient solutions for
adolescents [34].
There are notable strengths and limitations to report. The key strengths of our approach include
the elicitation of multiple stakeholder perspectives across the intervention development process, as
well as the ability to triangulate the input received from these stakeholders using qualitative research
methods. Another strength to our approach was that we preemptively discussed implementation
outcomes with the various stakeholders during the intervention development phase, which is expected
to maximize the intervention’s chances for success and sustainability. Conversely, this particular
approach raised stakeholder concerns related to implementation that have yet to be validated in a
randomized controlled trial.
The focus of the intervention on adolescents who are susceptible to tobacco use was another
strength. However, our study was limited by the small number of adolescent stakeholders
who reported any history of tobacco use—a critical subgroup whose perspectives may not have
been sufficiently addressed in the study. The low proportion of actual tobacco users relative to
susceptible individuals is typical in the adolescent population and may be misrepresented by potential
underreporting of tobacco use by study participants. Nevertheless, while thematic saturation was
reached overall with the 16 adolescent participants, it is unlikely that saturation was achieved with the
adolescent tobacco users in our sample.
In summary, stakeholder engagement ensured that the end-users (i.e., patients and clinic staff)
were represented in the development of the intervention. Citizen Scientists were also valuable partners
in implementation research because they were able to identify barriers and facilitators prior to
implementation. Even though the intervention is in the early stages of implementation and it is
premature to evaluate the full benefits of the engagement activities, the tool has been successfully
implemented in one clinic with few obstacles for over six months. Engaging key stakeholders
throughout the implementation process can improve the quality, applicability, and relevance of the
research, and enhance implementation success.
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